Veradermics Inc MANE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics to Present at Upcoming September Investor Conferences
A new version of an old drug is helping men grow back some of their hair
For the first time in decades, new hair-loss treatments are in the works. Here's how they're different.
Trading Information
- Previous Close Price
- $148.44
- Day Range
- $146.73–156.63
- 52-Week Range
- $32.00–156.63
- Bid/Ask
- $144.01 / $152.00
- Shares Outstanding
- 42.20M
- Market Cap
- $6.54B
- Volume/Avg
- 713,707 / 730,468
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 21
- Website
- https://www.veradermics.com
Valuation
Metric | MANE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.04 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MANE |
|---|---|
Quick Ratio | 70.25 |
Current Ratio | 70.53 |
Interest Coverage | — |
Quick Ratio
MANE
Profitability
Metric | MANE |
|---|---|
Return on Assets (Normalized) | −23.75% |
Return on Equity (Normalized) | −33.55% |
Return on Invested Capital (Normalized) | −36.89% |
Return on Assets
MANE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|VJ!YCb | LOCK|gv?x | $139B | |||
| Moderna Inc MRNA | LOCK|<%qh?>B | LOCK|#rN | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|&K&^sc | LOCK|yD<< | $99B | |||
| argenx SE ADR ARGX | LOCK|@LvTj> | LOCK|X$ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#R#Nz@Q | LOCK|Pl | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|<&WP&#z | LOCK|s!sc | $31B | |||
| Incyte Corp INCY | LOCK|lp&#%kx | LOCK|H$ | $25B | |||
| BioNTech SE ADR BNTX | LOCK|#<c>sC^ | LOCK|YJ# | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|!YY^wB | LOCK|#Y^b | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|nY%p^d | LOCK|?<D | $16B |
United States